Researchers have identified a series of 10 genes that may signify a trifecta of benefits for women diagnosed with ovarian cancer and ultimately reflect improved survival outcomes. The research found that the 10-gene biomarker panel may identify the aggressiveness of a patient’s disease, help predict survival outcomes and result in novel therapeutic strategies tailored to patients with the most adverse survival outcomes.